Summit TherapeuticsSMMT
SMMT
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 159
0
Funds holding %
of 7,290 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
26% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 34
14% more capital invested
Capital invested by funds: $1.65B [Q4 2024] → $1.89B (+$235M) [Q1 2025]
10% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 69
4% more funds holding
Funds holding: 202 [Q4 2024] → 210 (+8) [Q1 2025]
0.69% more ownership
Funds ownership: 12.56% [Q4 2024] → 13.25% (+0.69%) [Q1 2025]
31% less call options, than puts
Call options by funds: $45.5M | Put options by funds: $65.7M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
46%
upside
Avg. target
$38
85%
upside
High target
$44
114%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Reni Benjamin | 94%upside $40 | Market Outperform Reiterated | 2 Jun 2025 |
Goldman Sachs Salveen Richter | 99%upside $41 | Buy Maintained | 2 May 2025 |
Jefferies Kelly Shi | 114%upside $44 | Buy Maintained | 25 Apr 2025 |
Citigroup Yigal Nochomovitz | 70%upside $35 | Buy Upgraded | 26 Mar 2025 |
Evercore ISI Group Cory Kasimov | 46%upside $30 | Outperform Initiated | 12 Mar 2025 |
Financial journalist opinion
Based on 24 articles about SMMT published over the past 30 days
Neutral
PRNewsWire
12 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Business Wire
1 day ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 71,275 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committ.
Neutral
GlobeNewsWire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Neutral
Accesswire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Business Wire
2 days ago
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the progress of our organization, including the development of our innovative investigationa.
Positive
The Motley Fool
2 days ago
2 Soaring Stocks Wth More Upside Potential
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left.
Neutral
Accesswire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Positive
Zacks Investment Research
4 days ago
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Seeking Alpha
5 days ago
Summit Therapeutics: Market Overreaction Creates Opportunity
Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive but has not yet reached statistical significance; further follow-up may tip the balance. The recent stock sell-off reflects regulatory uncertainty rather than drug failure, creating a potential buying opportunity for long-term investors.
Negative
Zacks Investment Research
5 days ago
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
Charts implemented using Lightweight Charts™